Hybio Pharmaceutical Co., Ltd. (SHE:300199)

China flag China · Delayed Price · Currency is CNY
17.46
+0.26 (1.51%)
Mar 9, 2026, 3:04 PM CST
43.94%
Market Cap 15.42B
Revenue (ttm) 898.10M
Net Income (ttm) -67.50M
Shares Out 883.24M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,966,432
Average Volume 19,785,186
Open 17.05
Previous Close 17.20
Day's Range 16.39 - 17.61
52-Week Range 10.50 - 31.19
Beta 0.86
RSI 39.11
Earnings Date Apr 25, 2026

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermedia... [Read more]

Sector Healthcare
Founded 1998
Employees 1,035
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300199
Full Company Profile

Financial Performance

In 2024, Hybio Pharmaceutical's revenue was 590.20 million, an increase of 36.82% compared to the previous year's 431.38 million. Losses were -173.65 million, -66.21% less than in 2023.

Financial Statements

News

There is no news available yet.